Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

PHASE1UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2020

Conditions
Healthy MenMale Contraception
Interventions
DRUG

Placebo

Placebo with capsules that look like the 11β-MNTDC capsules but with no active ingredients

DRUG

11βmethyl nortestosterone dodecylcarbonate

Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC

Trial Locations (2)

90502

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance

98195

University of Washington, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

University of Washington

OTHER

collaborator

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

lead

Premier Research

OTHER